In contrast, its overexpression increases phosphorylation and activity of both TSC1 and TSC2, whereas increased phosphorylation of S6K1 and 4E-BP1 is observed in DYRK1A knockdown cancer cells—the effect inhibited by the mTOR-inhibiting drug rapamycin [46,47]. This evidence concerns the gene RPS6KB1 and cancer.